1. Home
  2. TBPH vs INNV Comparison

TBPH vs INNV Comparison

Compare TBPH & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • INNV
  • Stock Information
  • Founded
  • TBPH 2013
  • INNV 2007
  • Country
  • TBPH United States
  • INNV United States
  • Employees
  • TBPH N/A
  • INNV N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • INNV Medical/Nursing Services
  • Sector
  • TBPH Health Care
  • INNV Health Care
  • Exchange
  • TBPH Nasdaq
  • INNV Nasdaq
  • Market Cap
  • TBPH 464.5M
  • INNV 482.0M
  • IPO Year
  • TBPH N/A
  • INNV 2021
  • Fundamental
  • Price
  • TBPH $10.77
  • INNV $3.97
  • Analyst Decision
  • TBPH Buy
  • INNV Sell
  • Analyst Count
  • TBPH 3
  • INNV 2
  • Target Price
  • TBPH $11.33
  • INNV $5.00
  • AVG Volume (30 Days)
  • TBPH 379.4K
  • INNV 33.1K
  • Earning Date
  • TBPH 05-08-2025
  • INNV 05-06-2025
  • Dividend Yield
  • TBPH N/A
  • INNV N/A
  • EPS Growth
  • TBPH N/A
  • INNV N/A
  • EPS
  • TBPH N/A
  • INNV N/A
  • Revenue
  • TBPH $65,266,000.00
  • INNV $831,683,000.00
  • Revenue This Year
  • TBPH $51.09
  • INNV $13.77
  • Revenue Next Year
  • TBPH N/A
  • INNV $10.12
  • P/E Ratio
  • TBPH N/A
  • INNV N/A
  • Revenue Growth
  • TBPH 6.11
  • INNV 12.19
  • 52 Week Low
  • TBPH $7.44
  • INNV $2.60
  • 52 Week High
  • TBPH $11.82
  • INNV $6.69
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 64.32
  • INNV 57.37
  • Support Level
  • TBPH $9.10
  • INNV $3.82
  • Resistance Level
  • TBPH $11.82
  • INNV $4.15
  • Average True Range (ATR)
  • TBPH 0.39
  • INNV 0.21
  • MACD
  • TBPH 0.19
  • INNV -0.04
  • Stochastic Oscillator
  • TBPH 62.23
  • INNV 21.97

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About INNV InnovAge Holding Corp.

InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.

Share on Social Networks: